Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > HISTORY

<< Previous

Bullboard Posts

Next >>

Comment by Maxdudeon Feb 26, 2021 4:39pm

191 Views

Post# 32673935

RE:HISTORY

Thor..you have to keep in mind the share count increase by quite a bit...since 2017.

However, the value R-107 will offset this increase and add increase value to the SP....increaseing it's market cap.

As an investor..their webiste is classy and well done.

Israeli scientists are some of the best in the world.

If R-107 data points to a positive outcome, then we would have a rocket ship....wait until US investors get hold of a company like this.

Bought in on the US side yesterday...

JMHO

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages